BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2023 Earnings Call Transcript

Jean-Jacques Bienaime: One of the reasons why we decided to focus on the GKV and national price because we assume that it’s very likely there will not be an OBA with federal — their German federal government. And then so these prices might be a little lower than what we would potentially have had with OBA, but the net price will be about the same based on the fact that there is no — that we don’t have to reimburse the payers based on our patients going back to therapy after 3, 4 or 5 years. So net debt, we don’t anticipate. And based on our interaction with the GKV so far, it looks pretty promising, and we actually don’t anticipate any substantial — as Jeff said, any substantial difference with this approach.

Jeffrey Ajer: And then relative to your question about the cadence of VOXZOGO patient uptake, it’s — within kind of a band, it’s actually been pretty steady these last few quarters. Underneath that steady uptake, there’s a lot of individual market dynamics going on, but it comes on pretty smooth. I would suggest when modeling forward that you work from our revenue guidance that we’ve updated most recently and acknowledging that we’ve had a lot of updates to those revenue guidance in a positive direction. But yes, I’d fall back to that.

Operator: And that is all the time we have for questions today. I would like to turn the call back to BioMarin’s CEO, JJ Bienaimé, for closing remarks.

Jean-Jacques Bienaime: So in conclusion, we are very pleased with the booming progress in the first quarter and the continued successful launch of VOXZOGO around the world. The importance of our medicines to the people who rely on them is clear. And while sometimes the development path forward is not always clear cut, we will continue to push that in the interest of our patients. Thank you for your support, and have a good rest of the day.

Operator: The host has ended this call. Goodbye.